{
    "clinical_study": {
        "@rank": "136338", 
        "arm_group": [
            {
                "arm_group_label": "YVOIRE\u00ae contour", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Restylane SubQ\u2122", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is purposed to evaluate the efficacy and safety of YVOIRE\u00ae contour compared with\n      Restylane SubQ\u2122 injected into the anteromedial malar region."
        }, 
        "brief_title": "Clinical Study to Evaluate the Efficacy and Safety of YVOIRE\u00ae Contour Compared With Restylane SubQ\u2122 Injected Into the Anteromedial Malar Region", 
        "condition": "Normal, Healthy Adults With Moderate, Severe, or Very Severe Volume Loss of Anteromedial Malar Region", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Be male or female, 20-65 years of age\n\n          -  Have anteromedial malar region volume loss as grade 2, 3, or 4 on the Mid Face\n             Aesthetic Scale (MFAS) symmetrically on both sides\n\n          -  Desire filler treatment to correct volume loss in the anteromedial malar region\n\n          -  Accept the obligation not to receive any other mid facial procedures or treatments\n             during the study\n\n          -  Signed informed consent\n\n          -  Those who fall under one of the following 3 cases\n\n               1. Males or females who are surgically sterile\n\n               2. Post-menopausal females who are above 45 years of age and 2 years after the last\n                  menstruation\n\n               3. Fertile premenopausal females or males without having a surgical sterilization,\n                  who have agreed to use at least two contraception methods (one of the barrier\n                  methods must be included) for up to 14 days after the last treatment of the\n                  investigational device to avoid pregnancy\n\n        Exclusion Criteria:\n\n          -  Have a history of hypertrophic scars or keloids\n\n          -  Other criteria as identified in the protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "83", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02119780", 
            "org_study_id": "LG-HACL014"
        }, 
        "intervention": [
            {
                "arm_group_label": "YVOIRE\u00ae contour", 
                "description": "YVOIRE\u00ae contour injection into the anteromedial malar region", 
                "intervention_name": "YVOIRE\u00ae contour", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Restylane SubQ\u2122", 
                "description": "Restylane SubQ\u2122 injection into the anteromedial malar region", 
                "intervention_name": "Restylane SubQ\u2122", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 17, 2014", 
        "location": {
            "contact": {
                "email": "doctorseo@hotmail.com", 
                "last_name": "Seo"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul National University Hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "yaeom@lgls.com", 
            "last_name": "Yun-Ae Eom", 
            "phone": "82-2-6924-3157"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "South Korea: Ministry of Food and Drug Safety (MFDS)"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Mean of MFAS score as assessed by the independent blinded rater", 
            "measure": "Mid Face Aesthetic Scale (MFAS) score", 
            "safety_issue": "No", 
            "time_frame": "26 weeks after treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02119780"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Mean of MFAS score as assessed by the independent blinded rater", 
                "measure": "Mid Face Aesthetic Scale (MFAS) score", 
                "safety_issue": "No", 
                "time_frame": "2, 14, and 52 weeks after treatment"
            }, 
            {
                "description": "Changes of MFAS score as assessed by the independent blinded rater", 
                "measure": "Mid Face Aesthetic Scale (MFAS) score", 
                "safety_issue": "No", 
                "time_frame": "2, 14, 26, and 52 weeks after treatment"
            }, 
            {
                "description": "MFAS Responder (at least a one-point improvement on the MFAS) rate as assessed by the independent blinded rater", 
                "measure": "Mid Face Aesthetic Scale (MFAS) Responder rate", 
                "safety_issue": "No", 
                "time_frame": "2, 14, 26, and 52 weeks after treatment"
            }, 
            {
                "description": "Mean of GAIS score as assessed by subject", 
                "measure": "Global Aesthetic Improvement Scale (GAIS) score", 
                "safety_issue": "No", 
                "time_frame": "2, 14, 26, and 52 weeks after treatment"
            }, 
            {
                "description": "GAIS Responder (at least a one-point improvement on the GAIS) rate as assessed by subject", 
                "measure": "Global Aesthetic Improvement Scale (GAIS) Responder rate", 
                "safety_issue": "No", 
                "time_frame": "2, 14, 26, and 52 weeks after treatment"
            }
        ], 
        "source": "LG Life Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LG Life Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}